PDCD1 and triple-negative breast carcinoma: Novel targeted ICI therapies, including anti-PD-1 and anti-PD-L1 monoclonal antibodies, have shown efficacy against tumors such as lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and malignant melanoma [210,211,212,213].